Evidence map›Paper›PMID 31609925›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2019

PrEP Discontinuation and Prevention-Effective Adherence: Experiences of PrEP Users in Ugandan HIV Serodiscordant Couples.

Hannah N Gilbert, Monique A Wyatt, Emily E Pisarski, Timothy R Muwonge, Renee Heffron, Elly T Katabira, Connie L Celum, Jared M Baeten, Jessica E Haberer, Norma C Ware

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hannah N GilbertDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA.
Monique A WyattDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA.
Emily E PisarskiDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA.
Timothy R MuwongeInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Renee HeffronDepartments of Global Health.
Elly T KatabiraDepartment of Medicine, Makerere University, Kampala, Uganda.
Connie L CelumDepartments of Global Health.
Jared M BaetenDepartments of Global Health.
Jessica E HabererDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA.
Norma C WareDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA.

Funding

Optimizing Antiretroviral-Based HIV Prevention for HIV Serodiscordant CouplesR01MH095507 · NIMH · UNIVERSITY OF WASHINGTON · PI BAETEN, JARED · 2011 to 2020
$6.1M
Real World Adherence to HIV PrEP in Serodiscordant African CouplesR01MH098744 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI HABERER, JESSICA ELIZABETH · 2013 to 2017
$3.0M
Optimizing mHealth for adherence monitoring and interventionK24MH114732 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI HABERER, JESSICA ELIZABETH · 2017 to 2021
$800k
NIMH NIH HHS K24 MH114732NIMH NIH HHS R01 MH095507NIMH NIH HHS R01 MH098744
6 · The paper itself

Abstract

backgroundOptimal adherence to oral pre-exposure prophylaxis (PrEP) for HIV prevention involves aligning consistent PrEP use with periods of risk to achieve prevention-effective adherence. Prevention-effective adherence is predicated on individuals discontinuing PrEP during periods without expected risk. For stable, serodiscordant couples, antiretroviral therapy (ART) adherence by the HIV-positive partner markedly decreases HIV transmission risk, potentially obviating the need for continued PrEP use; yet little is known about actual lived experiences of discontinuing PrEP.

methodsIn-depth qualitative interviews were conducted with HIV-uninfected PrEP users in serodiscordant couples taking part in the Partners Demonstration Project at IDI-Kasangati, Kampala, Uganda. Open-ended interviews elicited information on the partnered relationship; understandings of PrEP; prevention strategies; and experiences of PrEP discontinuation. An inductive, thematic, content-analytic approach was used to analyze study data.

resultsUninfected partners experienced PrEP as a valued resource for preventing HIV acquisition. Despite ongoing ART use by HIV-positive partners for a period of time consistent with viral suppression, discontinuation of PrEP was experienced as a loss of protection and a corresponding increase in risk of HIV acquisition. Uninfected partners responded with strategies aimed at offsetting this subjective sense of increased risk, specifically: (1) changing sexual practices; (2) prioritizing fidelity in the relationship; (3) increasing reliance on condoms; and (4) seeking evidence of partners' ART adherence.

conclusionsThese experiences highlight the challenges PrEP users in serodiscordant couples face in discontinuing PrEP for prevention-effective adherence. Flexible interventions that support individuals during this transition may increase comfort with discontinuing PrEP when alternative prevention strategies provide protection, such as a partner's consistent adherence to ART.

Indexed as

Pre-Exposure ProphylaxisSafe SexAdultAnti-HIV AgentsAnti-Retroviral AgentsCondomsDisease Transmission, InfectiousFemaleHIV-1HIV InfectionsHumansMaleSexual BehaviorSexual PartnersUgandaYoung AdultAnti-HIV AgentsAnti-Retroviral Agents

Identifiers

PMID31609925
PMCPMC6812551

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.